Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPS1 | P31327 | 3/20 | 0.48 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.47 |
| ▸ | FEN1 | P39748 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4724651 | 0.84 | CPS1 (0.56) | CPS1KDM4ETSHRHPGDKMT2A | |
| SCHEMBL30309461 | 0.84 | CPS1 (0.56) | CPS1KDM4EEPHX2TSHRKMT2A | |
| SCHEMBL3396511 | 0.84 | CPS1 (0.56) | CPS1KDM4EEPHX2TSHRKMT2A | |
| SCHEMBL23981599 | 0.82 | L3MBTL3 (0.42) | ALOX5APFEN1HPGDKMT2A | |
| SCHEMBL2799115 | 0.82 | DGAT1 (0.49) | CPS1ALOX5APFEN1KDM4EEPHX2 | |
| SCHEMBL3093965 | 0.81 | MAPT (0.57) | CPS1ALOX5APFEN1KDM4EEPHX2 | |
| SCHEMBL20750338 | 0.81 | CPS1 (0.49) | CPS1KDM4E | |
| SCHEMBL9886019 | 0.80 | CPS1 (0.46) | CPS1ALOX5APFEN1KDM4EEPHX2 | |
| SCHEMBL21245854 | 0.79 | CPS1 (0.49) | CPS1ALOX5APFEN1KDM4EDPP4 | |
| SCHEMBL30198727 | 0.79 | CPS1 (0.49) | CPS1ALOX5APFEN1KDM4EDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210387981-A1 | TYK2 KINASE INHIBITORS | SAREUM LIMITED (GB) | 2021-12-16 | — | — | US | disclosed |
| EP-3864009-A1 | TYK2 KINASE INHIBITORS | Sareum Limited (GB) | 2021-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210387981-A1 | TYK2 KINASE INHIBITORS | TYK2, JAK1, JAK2 | CPS1 4726/4885ALOX5AP 4272/4885FEN1 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.